For full details on each session, please view the event guide.
8:00 am
Registration & Welcome Coffee
8:45 am Chair’s Opening Remarks
Humanised Mouse Models
9:00 am Targeting of Tumor-Specific HLA Ligands with Bispecific T Cell-Engaging Receptor (TCER™) Molecules
Synopsis
- XPRESIDENT® to exploit the repertoire of tumor-associated antigens
- Introduction into TCER™, Immatics’ TCR bispecific molecules
- TCER™ in vivo data
9:30 am Assessment of Different Humanised Mouse Models for the Evaluation of Cancer Immunotherapies
Synopsis
- Comparison of humanisation of immune system with huCD34+ HSC in different strains of immune-deficient mice (NSG, NSG SGM3, NOG & NOG-EXL)
- Evaluation of humanised PBMC mouse models
- Insight into the response of immunotherapies in different humanised mouse models with tumours (PDX and CDX)
10:00 am Advancing immuno-oncology therapies: what are the next generation syngeneic models?
Synopsis
- ICI Treatment & Dissecting the Mechanism Of Action (MOA)
- Immune Cells Impacting Syngeneic Tumorgenicity
- Tool GEMMs for MoA
10:30 am
Speed Networking & Morning Break
Syngeneic & PDX Models
11:30 am The Clinical IAP Antagonist ASTX660 Drives Anti-Tumor Immunity in T Cell Lymphoma
Synopsis
- ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, which has demonstrated preliminary evidence of single agent clinical activity in T cell lymphoma (TCL) patients
- To investigate the mechanism of action behind the single agent activity seen in the clinic we have used a comprehensive translational approach via the integration of in vitro coculture systems and in vivo preclinical models with human patient data from our clinical trial
- We describe a novel role for ASTX660 as an immunomodulatory molecule, capable acting on both the innate and adaptive immune system, which could be exploited to remodel the tumor immune microenvironment
12:00 pm Zebrafish Tumor Xenograft models: A new translational in-vivo tool for oncology drug discovery
Synopsis
- Zebrafish as in-vivo model system for oncology
- Zebrafish models for analysis of human tumor- and tumor-infiltrating cell interactions
- Zebrafish as complementary models to mouse PDX studies
12:15 pm Considerations for the correct implementation of PDX models in Immuno-Oncology
Synopsis
- What are Patient Derived Xenograft (PDX) models?
- Traditional versus humanised PDX models
- Generation of PDX models for Immuno-Oncology?
- Applications of PDX models in Immuno-Oncology
12:45 pm SubQperior: A Superior Syngeneic Model System to Subcutaneous Tumour Models
Synopsis
- Introducing the next generation of tumour models for immuno-oncology efficacy studies overcoming common problems experienced with subcutaneous tumour implantation
1:00 pm
Networking Lunch
2:00 pm Panel Discussion: Limitations of Humanised & PDX Models
Synopsis
- How can we push these borders to include more supporting immune cells, dendritic cells, NK-cells?
- Increasing longevity; CD34 humanised hyper immune-deficient mice can increase available study lengths but also increase the cost. Is there a middle ground?
- Gaining data on persistence of cellular therapies without requiring additional mice
2:45 pm Immune Checkpoints; Humanised Preclinical Models for Biologics’ Efficacy & MoA
Synopsis
- Exploring how model design impacts the physiological relevance and the predictability of preclinical outcomes
Afternoon Tea Break
Next Generation Preclinical Models for IO
3:30 pm Targeting Kras: Pros and Cons of In Vitro Tools Versus Mouse Models
Synopsis
- Can genetic models discriminate between tumour initiating and tumour maintaining effects of KRAS?
- Can we improve the identification of biomarkers for better treatment options?
- Can genetic models be used to predict the toxicity of new KRAS-specific drugs?
3:45 pm The Role of Biomarkers in the Transition from Preclinical Models to Clinical Trials in Immuno-Oncology
Synopsis
- Overview of different biomarkers and their functions
- Preclinical immuno-oncology models and biomarkers
- Brief discussion of biomarkers in immuno-oncology clinical trials
4:00 pm Round Table Discussion: Biomarkers in Immuno-oncology – From Preclinical Approaches Through Clinical Trials
Synopsis
- Discuss various biomarker platforms/technologies for preclinical immuno-oncology studies
- Discuss how the use of biomarkers in preclinical immuno-oncology studies can provide guidance for clinical studies
- Discuss biomarker approaches for immuno-oncology clinical trials
5:00 pm Drinks Reception & Round Table: What preclinical models provide a platform to assess immunotherapy toxicology?
Synopsis
Drinks Reception and Working Group Hosted by Crown Bio
• How to use mouse models to assess irAE?
• Looking at cytokine release in PBMC/CD34+ models – what does that tell us?
For full details on each session, please view the event guide.